Patents

Five things for pharma marketers to know: Tuesday, August 25

Five things for pharma marketers to know: Tuesday, August 25

By

US patent office declines to review two Ampyra patents; the FDA expands indication for Promacta; the Biosimilars Council argues against CMS proposal for biosimilar coding

Five things for pharma marketers to know, Thursday, June 4

Five things for pharma marketers to know, Thursday, June 4

By

Novartis appeals the ban on its biosimilar Zarxio; AbbVie petitions for distinct biosimilar labels; Sanofi will study Toujeo in a real-world setting

Five things for pharma marketers to know: Monday, June 1

Five things for pharma marketers to know: Monday, June 1

By

Bristol-Myers Squibb's Opdivo serves up lukewarm lung-cancer results; new cancer drugs are too expensive, Sloan Kettering oncologist tells ASCO attendees; Teva settlement could stymie industry use of pay-for-delay patent tactics

Five things for pharma marketers to know: Tuesday, May 5

Five things for pharma marketers to know: Tuesday, May 5

By

Worldwide spending on cancer medications hit $100 billion last year; Bayer adds an anticoagulant to its pipeline for $100 million; GlaxoSmithKline has a new chairman

Five things for pharma marketers to know: Friday, April 3

Five things for pharma marketers to know: Friday, April 3

By

Hedge fund activist challenges Shire patents; CMS issues documents on biosimilars; Astellas Pharma and the University of Texas MD Anderson Cancer Center partner on leukemia treatment

Five things for pharma marketers to know: Thursday, March 19

Five things for pharma marketers to know: Thursday, March 19

By

A Florida Congressman introduced a bill that would expand patent protections; Novo Nordisk expects to increase diabetes medication prices; AbbVie expanded its Alzheimer's research

Five things for pharma marketers to know: Wednesday, February 25

Five things for pharma marketers to know: Wednesday, February 25

By

J&J loses another Risperdal case; Pfizer slashes jobs at research center; Actavis challenges ulcerative colitis drug's patent.

Court invalidates patent for AstraZeneca asthma drug

A New Jersey District Court ruled that the Pulmicort Respules patent is invalid, opening the door for Actavis to launch a generic version of the billion-dollar asthma drug.

Five things for pharma marketers to know: Wednesday, February 11

Five things for pharma marketers to know: Wednesday, February 11

By

BMS loses breakthrough therapy status, Gilead's pricing comes under fire in Europe, and pharma fights Italy's off-label Avastin use.

Pfizer's Hospira deal shores up established product division

Pfizer's Hospira deal shores up established product division

By

Pfizer said the $17-billion decision to acquire Hospira will not affect the timeline of its divide-or-stay-whole decision.

Survey shows cancer cause-effect awareness lacking

A survey showed patients are not really clear on what causes cancer.

Pfizer quarter and year sales slip, CEO indicates M&A not pressing

Pfizer quarter and year sales slip, CEO indicates M&A not pressing

By

CEO Ian Read told investors the company has cash to make a deal, but there is no urgent need.

Five things for pharma marketers to know: Friday,  October 17

Five things for pharma marketers to know: Friday, October 17

By

Amgen sues Sanofi and Regeneron over PCSK9 patents; FDA panel wants Chantix black box to stay; Valeant-Allergan uproar rises in pitch; Pharmacyclics and Roche team up against CLL; and GSK's Ebola vax may "miss" the current crisis.

New exclusivity rules confound

A draft guidance publication date determines whether drugmakers get three or five years of market exclusivity.

NY sues over Forest Alzheimer's medication

NY's attorney general alleges that a formulation switch is an attempt to create monopoly.

J&J, Vivus patent suit ends

J&J subsidiary Janssen has abandoned its patent lawsuit over the anti-seizure medication topiramate, which is part of Vivus's prescription weight-loss drug Qsymia.

Eisai sues FDA for more patent life

The Japanese drugmaker is looking to add as much as a year onto the patent life of some of its drugs after the DEA dragged out their scheduling decisions.

FDA tackles women's sexual health

The regulator and patients will chat for two days in October.

Generic Viagra floods Brazil

The generic ED pills sell for five cents less than Pfizer's branded blue pill, but the undercutting is a bit deeper.

Pharma seeks to offload old drugs

The WSJ reports that Merck, Sanofi and GSK are looking to put older medications at arm's length.

Novartis lands Gleevec patent reprieve

Novartis lands Gleevec patent reprieve

By

Novartis and Sun agreed generic Gleevec won't surface until February 2016.

UK court OKs Herceptin biosimilar

A London court knocked down two Roche/Genentech patents, making a clearer path for biosimilars of the breast cancer drug. The primary patent lapses in July.

Lilly Alimta patent extended to 2022

Lilly Alimta patent extended to 2022

By

A court granted Lilly six more years of patent protection for the almost $3-billion-dollar-a-year cancer drug.

Survey shows Pharma digitally failing patients

Survey shows Pharma digitally failing patients

By

A study by consulting firm Accenture shows that patients not only expect digital outreach, but that their desire to be engaged is consistently being ignored.

Pfizer fights for Viagra patent

The company is suing Torrent Pharmaceuticals, which wants to market a drug before the patent lapses in 2019.

Celebrex patent loss to inflict EPS pain, but little more

Celebrex patent loss to inflict EPS pain, but little more

By

Analysts indicate the earlier-than-expected patent loss will not be a significant upset to Pfizer's present. The drugmaker plans to appeal the decision.

Quality, patents tax India connections

India's Ranbaxy logged yet another recall, while the country's stance on patent protection keeps the industry on edge.

Proposed budget gets mixed reviews

The White House's proposed FY 2015 budget gives an additional 1% to the FDA.

Lilly says 2014 will not be "trough year"

Lilly says 2014 will not be "trough year"

By

Higher prices helped insulate Q4 and annual sales, which fell and rose 2%, respectively. Lilly said its insulin glargine biosimilar will go nowhere if it is not substantially different from the competition.

Anti IP reform documents published

PMLive has documents that outline a strategy to keep intellectual property laws from relaxing in South Africa.


Email Newsletters


Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.